Cerus Corp. (CERS) announced a notable 15% increase in preliminary full-year product revenue from the previous year on Monday, surpassing its earlier guidance. The company anticipates a growth in product revenue of 8-11% by 2025.
For the full year of 2024, Cerus Corp. projects product revenues to reach $180.3 million, exceeding its initial guidance range of $177-$179 million. The company attributes this revenue growth to the sustained momentum of its Intercept platelet franchise.
Looking ahead, Cerus Corp. expects product revenues in 2025 to fall between $194 million and $200 million. Additionally, the company forecasts a year-over-year product revenue growth of approximately 10 to 15% for the first quarter of 2025 when compared to the first quarter of 2024.
